Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

NeoStem’s Eyre Subsidiary Approved to Use New Manufacturing Facility

publication date: Feb 1, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
NeoStem reported its China subsidiary, Suzhou Erye Pharma, was approved by the SFDA to begin manufacturing two penicillin products at the company’s new facility. The new plant will allow Eyre to increase production of solvent crystallization sterile penicillin by 50% and freeze-dried raw sterile penicillin by 100%. In the past, these two products have generated 20% of Erye's revenues. More details...

Stock Symbol: (NYSE Amex: NBS)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners